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PCR (3 assays, 2 gene targets, no virus recovered, no se-
quence obtained) from mallards in July (bird banding effort 
in Utah) and November (hunter harvest in Oregon) during 
surveillance in 2015–2016. Sequence of the HPAIV H5N2 
from a wild mallard during surveillance in 2016–2017, evi-
dence for continued evolution of this virus lineage, wide-
spread detections of HPAIV H5N2 in healthy wild birds 
(9), and lack of pathobiological effects in experimentally 
infected waterfowl (10) collectively provide strong evi-
dence for maintenance of HPAIV H5N2 in wild birds in 
North America. Detection of HPAIV in a mallard might im-
ply the potential for dissemination of HPAIV H5N2 during 
the southward fall migration of waterfowl in 2016.
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During 2010–2014, urgent care centers saw a ≈2-fold in-
crease in the number of visits for chlamydia and gonorrhea 
testing and a >3-fold increase in visits by persons with di-
agnosed sexually transmitted infections. As urgent care be-
comes more popular, vigilance is required to ensure proper 
management of these diseases.
Sexually transmitted infections (STIs) are the most com-monly reported nationally notifiable diseases in the Unit-
ed States (1), and annual medical costs for these diseases 
are estimated to exceed $16 billion (2). Reported rates of 
gonorrhea, chlamydia, and syphilis all increased from 2014 
to 2015, and antimicrobial drug–resistant gonorrhea remains 
an important concern (3). Therefore, proper diagnosis and 
treatment of these diseases is essential to reduce STI-associ-
ated morbidity rates and prevent further drug resistance (4).
Urgent care centers have been identified as appropri-
ate sources of care for nonemergency conditions that would 
otherwise be treated in a more costly emergency depart-
ment setting (5). These centers are proliferating across the 
country because of public demand for convenient care and 
the need to contain healthcare costs (6). The Urgent Care 
Association of America estimates that >9,000 of these cen-
ters are currently operating in the United States and, on 
average, each center sees ≈14,000 visits per year (7). Addi-
tionally, STI clinics are closing across the country because 
of decreased funding (8); therefore, urgent care centers 
might increasingly be a typical setting for STI diagnosis 
and treatment.
We found no literature describing the frequency of 
diagnosis and treatment of STIs in urgent care settings. 
Therefore, we set out to estimate the number of visits to ur-
gent care centers for the testing and diagnosis of chlamydia 
and gonorrhea.
For these analyses, we used data from the MarketScan 
commercially insured medical claims database for 2010, 
2012, and 2014 (9). We only included claims for visits to 
urgent care centers and aggregated these claims to provide 
numbers of visits for each patient. We then searched the 
claims for Current Procedural Terminology (CPT) codes 
and codes from the International Classification of Diseases, 
Ninth Revision, that indicated the testing or diagnosis of 
chlamydia, gonorrhea, or an “unspecified venereal disease” 
(Table). We counted visits that involved a test or diagnosis 
for each of the indicated diseases for each year and strati-
fied these results by percentage of female patients and the 
average age of the patients. We then used weights supplied 
in the dataset and calculated weighted numbers of visits. 
All analyses were conducted by using SAS 9.3 (SAS Insti-
tute, Cary, NC, USA).
Overall, we estimated a ≈2.5-fold increase dur-
ing 2010–2014 for all visits to urgent care centers (on-
line Technical Appendix, https://wwwnc.cdc.gov/EID/
article/23/2/16-1707-Techapp1.pdf). Among these vis-
its, we observed increases in the numbers of visits that 
involved STI testing or the treatment of patients with di-
agnosed STIs. During 2010–2014, a ≈1.5-fold increase 
occurred in visits that involved chlamydia testing and a 
≈2-fold increase in visits involving gonorrhea testing. 
We observed even larger increases in visits that involved 
diagnosed STIs. During the same period, we observed a 
≈6-fold increase in the numbers of visits that involved 





Table. Number of urgent care center visits by commercially insured patients during which the patient was tested for gonorrhea or 
chlamydia or treated for a diagnosed sexually transmitted infection, United States, 2010–2014* 
Characteristic 2010 2012 2014 
Total visits† 
 Unweighted 1,197,720 2,603,234 4,075,379 
 Weighted‡ 47,000,000 99,000,000 155,000,000 
 % Female 81.5 81.7 81.9 
 Average age, y 30.7 35.6 36.3 
Visits during which a chlamydia test was performed (CPT codes 87110, 87270, 87320, 87490, 87491, 87492, 87810) 
 Unweighted 1,293 2,090 3,711 
 Weighted 51,701 76,746 136,167 
 % Female 81.8 79.4 76.6 
 Average age, y 31.0 29.6 30.7 
Visits during which a gonorrhea test was performed (CPT codes 87590, 87591, 87592, 87850) 
 Unweighted 1,174 1,885 3,665 
 Weighted 47,747 69,665 134,403 
 % Female 82.6 80.1 76.5 
 Average age, y 31.2 29.8 29.9 
Visits during which diagnosed chlamydia was treated (ICD-9 codes 079.88, 079.98, 099.41, 099.50–099.56, 099.59) 
 Unweighted 133 430 988 
 Weighted 4,004 12,152 29,291 
 % Female 59.4 56.7 61.3 
 Average age, y 29.7 27.0 26.8 
Visits during which a diagnosed “unspecified venereal disease” was treated (ICD-9 codes 099.8, 099.9) 
 Unweighted 155 406 1,260 
 Weighted 4,655 11,392 35,550 
 % Female 55.3 49.6 50.4 
 Average age, y 30.1 30.1 31.0 
Visits during which diagnosed gonorrhea was treated (ICD-9 code 098) 
 Unweighted 116 224 522 
 Weighted 3,000 6,074 13,783 
 % Female 41.8 53.5 47.0 
 Average age, y 30.3 29.1 30.2 
*CPT, Current Procedural Terminology; ICD-9, International Classification of Diseases, Ninth Revision; STI, sexually transmitted infection. 
†Includes all patients seeking care at urgent care centers for any reason. 
‡Estimates are rounded to the nearest million. 
 
diagnosed chlamydia, a >3-fold increase in the numbers 
of visits that involved diagnosed gonorrhea, and a ≈6-fold 
increase in the numbers of visits that involved an unspeci-
fied diagnosed STI. Most visits that involved STI test-
ing were made by female patients; the average age for 
all patients at these visits was 28.1 years. Most visits by 
a patient for diagnosed chlamydia were made by female 
patients; the average age for all patients at these visits was 
27.8 years. The number of visits by patients for an un-
specified diagnosed STI was nearly evenly split between 
male and female patients; the average age of all patients at 
these visit was 30.4 years. The visits for diagnosed gonor-
rhea were predominantly made by male patients; the aver-
age age of all patients at these visits was 29.9 years.
Visits to urgent care centers have increased over 
time, and our findings demonstrate that visits to urgent 
care centers for STI care in particular have dramatically 
increased. Previous work has highlighted differences in 
the use of antibiotics to treat chlamydia in emergency de-
partments compared with physician offices (10) suggest-
ing that differences might also exist in the treatment of 
STIs in urgent care centers compared with other health-
care settings. Given the increases in STIs, increases in 
antimicrobial drug resistance, and increases in use of ur-
gent care centers for STI care, further work is needed to 
determine how STIs are being managed in this venue to 
ensure quality care.
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